Julie M Cherrington

Julie M Cherrington, Ph.D. is an experienced life science executive with extensive insight into bringing drugs into the clinic and through to commercialization.

Dr. Cherrington is also a successful company builder – she has served as President and Chief Executive Officer for several biotechnology companies, including QUE Oncology, Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Dr. Cherrington received her Ph.D. training in microbiology and immunology from the University of Minnesota and Stanford University and completed a postdoctoral fellowship at the University of California, San Francisco.

Currently, Dr. Cherrington serves on the Boards of Syncona Ltd, Mirati Therapeutics, Sar-dona Therapeutics, KisoJi Biotechnology, MycRx, and Actym